Ankylosing spondylitis is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized diagnosis are critical to improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory examination and pathological activation.
Platforms can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of ankylosing spondylitis of ankylosing spondylitis syndrome require individual development, typically including multidimensional management, including drug therapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of ankylosing spondylitis associated with synthetase syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.